A worldwide overview for hexavalent vaccines and a glimpse into Turkiye’s perspective

Figures & data

Table 1. Use of acellular hexavalent vaccines in immunization schemes.⁷¹

Counrty	Use of hexavalent vaccines
South Africa	6,10,14w, 18 m
Argentina	2,4,6 m
Bahamas	2,4,6 m
Barbados	2,4,6 m
Canada	2,4,6 m
Chile	2,4,6,18 m
Mexico	2,4,6,18 m
Panama	2,4,6,18 m
United States of America	2,4,6 m
United Arab Emirates	2,4 m
Bahrain	2,4 m
Jordan	3,4,5 m
Libya	2,4,6 m
Oman	2,4 m
Qatar	2,4 m
Saudi Arabia	2,4,6 m
Andorra	2,4,12 m
Armenia	6,12,18w
Austria	2,4,10-11 m
Belgium	8,12,16w and 15 m
Bulgaria	2,3,4 m
Czech Republic	3,5,11 m
Croatia	2,4,18 m
Estonia	3, 4.5, 6 m and 2y
France	2,4,11 m
Georgia	2,3,4 m
Germany	2,3,4,11 m
Ireland	2,4,6 m
Italy	3, 5, 11 m
Kazakhstan	2,4 m
Luxembourg	2,3 m
Latvia	2,4,6,12-15 m
Monaco	2,4,11 m
North Macedonia	2,6 m
Malta	2,3,4,18 m
Netherlands	2*,3,5,11 m
Norway	2,5,12 m
Portugal	2,6 m
Russian Federation	3,4.5,6,18 m
Romania	2,4,11 m
San Marino	3,5,11 m
Slovenia	3,5,11-18 m
Slovakia	2,4,10 m
Spain	2,4,11 m
Sweden	3,5, 12 m
Switzerland	2,4,12 m
UK (United Kingdom of Great Britain and Northern Ireland)	8,12,16w
Australia	2,4,6 m
Brunei Darussalam	2,4,6 m
Malaysia	2,3,5,18 m
New Caledonia	2,11 m
Niue	6w, 3,5 m
New Zealand**	6w, 3,5 m
French Polynesia	2,10 m
Wallis and Futuna	2,11 m

w: week; m: month; y: year

*Additional vaccination at month 2 when mother is not vaccinated against pertussis during pregnancy and in some other special situaions.

**Revaccination for children aged < 10y post HSCT or chemotherapy, pre- or post- splenectomy, pre- or post-solid organ transplant, dialysis, or other severely.

Table 2. Turkiye’s national childhood immunization program.

Active Ingredients	At birth	End of the 1st month	End of the 2nd month	End of the 4th month	End of the 6th month	End of the 12th month	End of the 18th month	End of the 24th month	End of the 48th month	13 years
Hepatitis B	I	II			III
BCG			I
PCV-13			I	II		B
DTaP-IPV-Hib			I	II	III		B
OPV					I		II
VAR						I
MMR						I			II
Hepatitis A							II	II
DTaP-IPV									B
Td										B

BCG: Tuberculosis, PCV: Pneumococcal Conjugated Vaccine D: Diphtheria; aP: Acellular Pertussis; T: Tetanus; IPV: Inactivated Polio Vaccine; Hib: Haemophilus influenzae type B; OPV: Oral Polio Vaccine; VAR: Varicella Vaccine, MMR: Measles, Mumps, Rubella; B: Booster; Td: Tetanus, Diphtheria.

Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt H-J, von Kries R. Effectiveness of hexavalent vaccines against invasive haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008;26(20):2545–52. doi:10.1016/j.vaccine.2008.03.001.

 PubMed Web of Science ®Google Scholar